Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06727604 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Phase 2 study of Graves Disease, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06727604: Recruiting Phase 2 study of Graves Disease, sponsored by Immunovant Sciences.
NCT06727604 is a Phase 2 study of Graves Disease that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 240 participants, below the 288-participant average among 11 other Graves Disease trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06727604, a Phase 2 study of Graves Disease, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
California
- Site Number - 1061 - Huntington Beach
- Site Number - 1001 - Los Angeles
- Site Number - 1062 - Orange
- Site Number - 1046 - Sacramento
- Site Number - 1034 - San Francisco
- Site Number - 1035 - Santa Clarita
- Site Number - 1005 - Torrance
- Site Number - 1006 - Walnut Creek
Florida
- Site Number - 1029 - Clearwater
- Site Number - 1055 - Jacksonville
- Site Number - 1056 - Jacksonville
- Site Number - 1028 - Miami
- Site Number - 1064 - Ocoee
- Site Number - 1011 - Orlando
- Site Number - 1016 - Port Charlotte
Arizona
- Site Number - 1032 - Phoenix
- Site Number - 1036 - Phoenix
Colorado
- Site Number - 1013 - Englewood
Delaware
- Site Number - 1010 - Newark
District of Columbia
- Site Number - 1040 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT06727604 shows while recruiting
NCT06727604 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 288-participant average among 11 other Graves Disease trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06727604 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06727604 about?
NCT06727604 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease". This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 ...
What is the current status of trial NCT06727604?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-12-17. Estimated completion is 2028-06.
What conditions does trial NCT06727604 study?
This clinical trial studies the following conditions: Graves Disease.
What interventions are being tested in trial NCT06727604?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT06727604?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06727604 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06727604's enrollment target sits among peer trials
240 2nd of 11 the highest of 11 other Graves Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
-
Radioactive Iodide Therapy for Pediatric Graves' Disease
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
COMPLETED · Phase 2
-
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
RECRUITING · Phase 1
-
Study of BHV-1300 in Graves' Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI